Cowen reissued their hold rating on shares of Puma Biotechnology (NASDAQ:PBYI) in a research note issued to investors on Friday. Cowen currently has a $80.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also weighed in on the stock. BidaskClub lowered shares of Puma Biotechnology from a hold rating to a sell rating in a research report on Saturday, July 28th. Citigroup raised their price objective on shares of Puma Biotechnology from $146.00 to $164.00 and gave the company a buy rating in a research report on Thursday, June 28th. ValuEngine lowered shares of Puma Biotechnology from a sell rating to a strong sell rating in a research report on Tuesday, May 22nd. Stifel Nicolaus reduced their price objective on shares of Puma Biotechnology from $95.00 to $87.00 and set a buy rating for the company in a research report on Friday, May 11th. Finally, Zacks Investment Research lowered shares of Puma Biotechnology from a buy rating to a hold rating in a research report on Wednesday, May 9th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $101.40.

Puma Biotechnology stock traded down $3.95 during trading hours on Friday, hitting $44.70. 4,184,421 shares of the company traded hands, compared to its average volume of 602,710. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -5.69 and a beta of -0.10. The company has a current ratio of 1.91, a quick ratio of 1.87 and a debt-to-equity ratio of 0.85. Puma Biotechnology has a 1-year low of $44.50 and a 1-year high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.26) by $0.09. The business had revenue of $50.80 million for the quarter, compared to the consensus estimate of $45.67 million. During the same quarter last year, the business posted ($1.38) EPS. research analysts expect that Puma Biotechnology will post -3.68 earnings per share for the current fiscal year.

In other Puma Biotechnology news, insider Richard Paul Bryce sold 1,836 shares of the firm’s stock in a transaction dated Friday, July 20th. The shares were sold at an average price of $51.95, for a total value of $95,380.20. Following the completion of the transaction, the insider now directly owns 32,543 shares in the company, valued at $1,690,608.85. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Charles R. Eyler sold 1,211 shares of the firm’s stock in a transaction dated Friday, June 1st. The stock was sold at an average price of $53.00, for a total transaction of $64,183.00. Following the completion of the transaction, the insider now owns 35,816 shares of the company’s stock, valued at $1,898,248. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,567 shares of company stock valued at $810,603. Corporate insiders own 21.50% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the business. State of Wisconsin Investment Board boosted its holdings in shares of Puma Biotechnology by 3.8% in the second quarter. State of Wisconsin Investment Board now owns 29,700 shares of the biopharmaceutical company’s stock worth $1,757,000 after buying an additional 1,100 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Puma Biotechnology by 307.1% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,547 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 1,167 shares during the period. Creative Planning boosted its holdings in shares of Puma Biotechnology by 30.1% in the second quarter. Creative Planning now owns 5,129 shares of the biopharmaceutical company’s stock worth $303,000 after buying an additional 1,188 shares during the period. Swiss National Bank boosted its holdings in shares of Puma Biotechnology by 2.4% in the first quarter. Swiss National Bank now owns 51,930 shares of the biopharmaceutical company’s stock worth $3,534,000 after buying an additional 1,200 shares during the period. Finally, Xact Kapitalforvaltning AB boosted its holdings in shares of Puma Biotechnology by 50.7% in the first quarter. Xact Kapitalforvaltning AB now owns 4,458 shares of the biopharmaceutical company’s stock worth $303,000 after buying an additional 1,500 shares during the period. Institutional investors own 91.97% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).

Featured Article: Trading Strategy Methods for Individual Investors

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.